Inpharma Weekly

, Volume 1062, Issue 1, pp 7–8 | Cite as

New targets may lead to novel classes of anti-obesity drugs

  • Gill Higgins
Newsletter Article


Although a number of appetite suppressants are now in clinical trials, the search for new anti-obesity drug targets continues. Recent advances in basic science have unveiled 2 new receptors that may prove to have potential in this field. They are the neuropeptide Y (NPY)-5 receptor and the peroxisome proliferator activated receptor (PPAR)-γ. These possible new approaches to the treatment of obesity were discussed at the 3rd IBC USA conference on ‘Obesity - Advances in Understanding and Treatment’ [ San Diego, US; September 1996 ].


Obesity Feeding Behaviour Peroxisome Proliferator Activate Receptor Pancreatic Polypeptide Eicosan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1996

Authors and Affiliations

  • Gill Higgins

There are no affiliations available

Personalised recommendations